

**University of Plymouth**

**PEARL**

**<https://pearl.plymouth.ac.uk>**

---

Faculty of Health: Medicine, Dentistry and Human Sciences

Peninsula Medical School

---

2021-03

- mediates inositol 1,4,5-Trisphosphate receptor ubiquitination and degradation. *J Biol Chem* 2011;286:24426–24433.
- Alzami AM, Adly N, Al Dhalaan H, Alkuraya FS. A nullimorphic ERLIN2 mutation defines a complicated hereditary spastic paraplegia locus (SPG18). *Neurogenetics* 2011;12:333–336.
  - Novarino G, Fenstermaker AG, Zaki MS, et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. *Science* 2014;343:506–511.
  - Wagner M, Osborn DP, Gehweiler I, et al. Bi-allelic variants in RNF170 are associated with hereditary spastic paraplegia. *Nat Commun* 2019;10:4790.
  - Valdmanis PN, Dupre N, Lachance M, et al. A mutation in the RNF170 gene causes autosomal dominant sensory ataxia. *Brain* 2011;134:602–607.
  - Morais S, Raymond L, Mairey M, et al. Massive sequencing of 70 genes reveals a myriad of missing genes or mechanisms to be uncovered in hereditary spastic paraplegias. *Eur J Hum Genet* 2017;25:1217–1228.
  - Larcher L, Norris JW, Lejeune E, et al. The complete loss of function of the SMS gene results in a severe form of Snyder-Robinson syndrome. *Eur J Med Genet* 2020;63(4):103777.
  - Nagy E, Maquat LE. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. *Trends Biochem Sci* 1998;23:198–199.

## Brain Microglial Activation Increased in Glucocerebrosidase (*GBA*) Mutation Carriers without Parkinson's disease

Stephen Mullin, MRCP, PhD,<sup>1,2†</sup> Morten Gersel Stokholm, MD, PhD,<sup>3†</sup> Derralyn Hughes, FRCP, PhD,<sup>4</sup> Atul Mehta, FRCP, PhD,<sup>4</sup> Peter Parbo, MD, PhD,<sup>3</sup> Rainer Hinz, PhD,<sup>5</sup>

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

\*Correspondence to: Prof. Anthony HV Schapira, UCL, Institute of Neurology, Royal Free Campus, Rowland Hill Street, Hampstead, London NW3 2PF, UK; E-mail: a.schapira@ucl.ac.uk

†Joint first authorship.

‡Joint last authorship.

**Relevant conflicts of interest/financial disclosures:** There were no conflicts of interest. S.M. is a National Institute for Health Research-supported clinical lecturer.

**Funding agencies:** This research was funded by the Medical Research Council (MR/J009660/1 COEN 1), MRC Experimental Medicine (MR/M006646/1), and Joint Programme Neurodegenerative Disease Research (MR/N028651/1) and was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. SM is a National Institute for Health Research supported clinical lecturer. Independent Research Fund Denmark, Lundbeck Foundation, Kattan Trust (285), and Joint Programme Neurodegenerative Disease Research (MR/N028651/1). Funders had no role in data analysis and did not have access to the data set.

**Received:** 15 July 2020; **Revised:** 11 October 2020; **Accepted:** 19 October 2020

Published online 5 December 2020 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28375

Nicola Pavese, MD, PhD,<sup>3,6</sup> David J. Brooks, FRCP, DSc, FMedSci,<sup>3,6†</sup> and Anthony H.V. Schapira, FRCP, FMedSci<sup>1,7†\*</sup>

<sup>1</sup>Department of Clinical and Movement Neurosciences, Institute of Neurology, UCL, London, UK <sup>2</sup>Institute of Health and Care Research, University of Plymouth Peninsula School of Medicine, Plymouth, UK <sup>3</sup>Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark <sup>4</sup>Department of Haematology, Institute of Immunity and Transplantation, UCL, London, UK <sup>5</sup>Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK <sup>6</sup>Institute of Translational and Clinical Research, Newcastle University, Newcastle, UK <sup>7</sup>Lysosomal storage disease unit, Royal Free Hospital, London, UK

**ABSTRACT: Background:** Glucocerebrosidase gene mutations are a common genetic risk factor for Parkinson's disease. They exhibit incomplete penetrance. The objective of the present study was to measure microglial activation and dopamine integrity in glucocerebrosidase gene mutation carriers without Parkinson's disease compared to controls.

**Methods:** We performed PET scans on 9 glucocerebrosidase gene mutation carriers without Parkinson's disease and 29 age-matched controls. We measured microglial activation as <sup>11</sup>C-(R)-PK11195 binding potentials, and dopamine terminal integrity with <sup>18</sup>F-dopa influx constants.

**Results:** The <sup>11</sup>C-(R)-PK11195 binding potential was increased in the substantia nigra of glucocerebrosidase gene carriers compared with controls (Student *t* test; right, *t* = −4.45, *P* = 0.0001). Statistical parametric mapping also localized significantly increased <sup>11</sup>C-(R)-PK11195 binding potential in the occipital and temporal lobes, cerebellum, hippocampus, and mesencephalon. The degree of hyposmia correlated with nigral <sup>11</sup>C-(R)-PK11195 regional binding potentials (Spearman's rank, *P* = 0.0066). Mean striatal <sup>18</sup>F-dopa uptake was similar to healthy controls.

**Conclusions:** In vivo <sup>11</sup>C-(R)-PK11195 PET imaging detects neuroinflammation in brain regions susceptible to Lewy pathology in glucocerebrosidase gene mutation carriers without Parkinson's. © 2020 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

**Key Words:** Parkinson's disease; microglia; substantia nigra; glucocerebrosidase; positron emission tomography

The glucocerebrosidase gene (*GBA*) encodes the lysosomal hydrolase glucocerebrosidase. In the biallelic (homozygous or compound heterozygous) state, *GBA* mutations may cause Gaucher disease (GD) which leads

to glucosylceramide accumulation in visceral organs and, in a minority of cases, the central nervous system (neuronopathic GD). *GBA* mutations are the most significant genetic risk factor for Parkinson's disease (PD) and dementia with Lewy bodies (DLB)<sup>1-3</sup>; however, penetrance is only 10%–30%.<sup>4-6</sup> PD patients carrying a *GBA* mutation have an earlier disease onset and a higher risk of dementia.<sup>7</sup>

At postmortem,  $\alpha$ -synuclein aggregations identical to those found in idiopathic PD<sup>1</sup> and DLB<sup>8</sup> are present in *GBA*-PD subjects. Asymmetrically reduced striatal <sup>18</sup>F-dopa uptake,<sup>9,10</sup> striatal dopamine transporter binding,<sup>11,12</sup> and an altered striatal asymmetry index<sup>13</sup> have been reported in PD patients with *GBA* mutations. Conversely <sup>123</sup>I-isoflupane dopamine transporter uptake has been demonstrated to be upregulated in non-PD *GBA* carriers compared with controls and is higher in *GBA* PD compared to idiopathic PD cases.<sup>14,15</sup> *GBA* mutation carriers without PD exhibit prodromal PD features,<sup>16-19</sup> which progress with time.<sup>20</sup>

Glial activation has been demonstrated in postmortem PD brains.<sup>21,22</sup> Nigral microglial activation along with reduced striatal <sup>18</sup>F-Dopa uptake is present in idiopathic rapid eye movement sleep behavior disorder (RBD).<sup>23</sup> It is also a feature of neuronopathic GD at postmortem<sup>8</sup> and in GD mouse models.<sup>24</sup> No studies have investigated in vivo the presence of brain microglial activation in *GBA* mutation carriers and related this to the presence of striatal dopaminergic dysfunction. We therefore measured <sup>11</sup>C-(R)-PK11195 regional binding potentials (BP<sub>ND</sub>) and <sup>18</sup>F-dopa K<sub>i</sub> in *GBA* mutation carriers without evidence of Parkinson's disease.

## Methods

### Recruitment and Clinical Assessments

Between 2015 and 2016, 9 biallelic (homozygous or compound heterozygous) or heterozygous carriers of *GBA* mutations were recruited from University College London, UK (see Table 1 for characteristics). All subjects had exons 1–11 of the *GBA* gene sequenced (Table 1). Biallelic carriers had type 1 GD, whereas heterozygous carriers were drawn from GD kindreds. No subjects met PD (UK Brain Bank) diagnostic criteria, and none were genetically related. Two of 5 GD patients were receiving enzyme replacement therapy (ERT; velaglucerase 800 IU weekly and 4000 IU monthly) and 3 of 5 substrate reduction therapy (SRT: eligustat 84 IU twice daily in 2 of 3, miglustat 300 mg once daily in 1 of 3). Both SRT and ERT were administered throughout the duration of the study. Ethical approval was obtained from London, UK

(10/H0720/21), and Midtjylland, Denmark (M-2014-397-14), research ethics committees.

Each *GBA* carrier had <sup>11</sup>C-(R)-PK11195 and <sup>18</sup>F-dopa PET, an MRI, and neurological examination. Prodromal PD features were rated with the University of Pennsylvania Smell Identification Test (UPSIT), Montreal cognitive assessment, RBD questionnaire (RBDSQ), PD Non-Motor Symptoms Scale, the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts II and III, and Beck's Depression Inventory.

All scans and examinations were performed at Aarhus University Hospital, Denmark. *GBA* carrier PET findings were compared with in-house PET data from 29 age-matched healthy controls (20 had <sup>11</sup>C-[R]-PK11195 BP<sub>ND</sub> PET, and 9 had <sup>18</sup>F-dopa PET) recruited for a previously published study.<sup>25</sup> Assessments of control prodromal PD features were not available.

### PET and MRI

We performed prespecified region-of-interest (ROI) analyses comparing *GBA* mutation carriers with controls. Selected ROIs were the substantia nigra (SN), putamen, and caudate for <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub> and the putamen and caudate for <sup>18</sup>F-dopa K<sub>i</sub>. We performed statistical parametric mapping (SPM) of <sup>11</sup>C-(R)-PK11195 uptake across all brain voxels. Technical details of the PET and MRI scanning and analysis procedures are available in the supplementary materials.

### Statistics

For the ROI analyses, statistical calculations and graphs were produced with Stata v14.2 software (StataCorp., College Station, TX). The <sup>18</sup>F-dopa K<sub>i</sub> and <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub> values from specified ROIs were compared in carrier and control groups using the Student *t* test ( $P < 0.05$ ). When there was a significant difference in <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub> between the *GBA* and control groups, secondary analyses correlating PD prodromal features with <sup>11</sup>C-(R)-PK11195BP<sub>ND</sub> were undertaken (Spearman's rank: all clinical scales were non normally distributed,  $P < 0.05$ ). A Bonferroni correction was applied to all significant results.

## Results

### Participants

Participant characteristics are listed in Table 1. Nine *GBA* mutation carriers (5 biallelic and 4 heterozygous) were selected on the basis of their genotype and the absence of PD features. Two age-matched control groups (20 for <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub> PET and 9 for <sup>18</sup>F-dopa PET) were included in the final *GBA* analysis. Some GD patients had musculoskeletal problems typical of GD reflected in raised MDS UPDRS III scores, but these were not specific for PD. This reflects the limitations of the MDS UPDRS when used in the context of non-PD

**TABLE 1.** Characteristics of control and *GBA* carrier groups

	Biallelic <i>GBA</i> (n = 5)	Heterozygous <i>GBA</i> (n = 4)	Combined <i>GBA</i> (n = 9)	<sup>11</sup> C-(R)-PK11195 controls (n = 20)	<sup>18</sup> F-Dopa controls (n = 9)		
Age, years	62.6 (2.9)	63.3 (7.7)	62.9 (2.9)	66.8 (6.0)	64.6 (3.6)		
Male, %	40.0	50.0	44.4	60.0	100.0		
UPSIT	33.6 (1.1)	31.5 (3.9)	32.7 (2.7)				
MoCA	27.4 (1.9)	27.8 (2.2)	27.6 (1.9)				
MDS UPDRS II	2.0 (2.1)	3.0 (3.6)	2.4 (2.7)				
MDS UPDRS III	12.8 (10.4)	4.5 (2.4)	9.1 (8.7)				
BDI	2.6 (2.7)	4.0 (1.4)	3.2 (2.2)				
NMSS	13.8 (9.2)	17.0 (10.4)	15.2 (9.3)				
RBDSQ	2.0 (1.9)	4.5 (2.4)	3.1 (2.4)				
Mutations of <i>GBA</i> group							
	Gaucher disease	Enzyme replacement therapy	Substrate reduction therapy				
N370s/L444P <sup>a</sup>	Yes	No	Yes				
N370S/IVS2 + 1 <sup>a</sup>	No	No	Yes				
N370S/F216Y	Yes	Yes	No				
N370S/R359X <sup>b</sup>	Yes	No	Yes				
N370S/V447E	Yes	Yes	No				
RecNcil (L444P/A456P/V460V) <sup>a</sup> /wt	No	No	No				
N370S/wt	No	No	No				
N370S/wt	No	No	No				
V394L <sup>a</sup> /wt	No	No	No				
Clinical scores of <i>GBA</i> carriers							
Participant	MDS UPDRS II	MDS UPDRS III	MoCA	UPSIT	BDI	NMSS	RBDSQ
1	0	2	30	37	4	15	7
2	0	3	25	30	2	4	2
3	2	4	30	35	2	8	1
4	5	29	26	32	3	13	4
5	0	4	26	33	7	28	4
6	3	11	29	34	1	16	1
7	0	7	27	31	5	29	0
8	2	6	29	28	5	20	1
9	0	16	26	34	0	4	0

*GBA*, glucocerebrosidase; PD, Parkinson's disease; MDS UPDRS, Movement Disorder Society Unified Parkinson's Disease Rating Scale; NMSS, Non-Motor Symptoms Scale; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; BDI, Beck's Depression Index; RBDSQ, REM Sleep Behavior Disorder Questionnaire.

For demographics, results are mean (SD).

<sup>a</sup>Severe mutation of *GBA* carrier group.

<sup>b</sup>Null mutation of *GBA* carrier group.

comorbidities and applied to subjects without diagnosed PD. No participants had a bradykinetic or rigid syndrome on expert examination. There were no missing data.

### Substantia Nigra <sup>11</sup>C-(R)-PK11195 BPND Is Increased in *GBA*+ Individuals Compared With Controls

ROI analysis localized a significant increase in mean nigral <sup>11</sup>C-(R)-PK11195 BPND of the *GBA* carriers compared with controls (Student *t* test, *t* = -4.45, *P* = 0.0001; Tables S1 and S2). Statistical significance was retained after correction for multiple comparisons (Table S2). For the *GBA* mutation carriers, mean SN <sup>11</sup>C-(R)-PK11195 BPND was 0.15 ± 0.08 compared with -0.01 ± 0.09 for the control group (Table S1 and Fig. 1A). Interestingly,


heterozygous carriers had disproportionately higher BP<sub>ND</sub> than biallelic (GD) patients (Table S1 and Fig. 1A).

### <sup>11</sup>C-(R)-PK11195 BPND Correlates With Olfactory Deficit in *GBA*+ Individuals

There was a negative correlation between nigral <sup>11</sup>C-(R)-PK11195 BPND and UPSIT scores in *GBA* mutation carriers (Spearman's rank, *P* = 0.0066; Table S2 and Fig. 1D), which did not survive correction for multiple comparisons (Table S2).

### Upregulated Cortical, Hippocampal, and Mesencephalon <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub> in *GBA*+ Group

SPM-localized clusters of voxels with significantly increased <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub> in *GBA* carriers



**FIG. 1.** (A) Top left, box and dot plots of  $^{11}\text{C}$ -PK11195 binding potential ( $\text{BP}_{\text{ND}}$ ) in the substantia nigra of *GBA*+ heterozygous carriers (white circles), biallelic *GBA*+ carriers (black circles), and controls (hollow black diamonds). Please note data points are offset across x axis for ease of interpretation. Middle line is median, box is interquartile range. (B) Top right,  $^{11}\text{C}$ -PK11195 binding potential ( $\text{BP}_{\text{ND}}$ ) in *GBA* carriers > controls. Colored areas depicted on the single-subject brain template illustrate clusters of voxels of  $^{11}\text{C}$ -PK11195 binding potential ( $\text{BP}_{\text{ND}}$ ) surviving  $P < 0.05$  with family-wise error rate (FWE) correction in the brain stem region of *GBA*+ carriers compared with control subjects. Non-brain stem clusters are masked. *GBA*,  $n = 9$ ; controls,  $n = 20$ . (C) Bottom left,  $^{11}\text{C}$  PK11195 binding potential ( $\text{BP}_{\text{ND}}$ ) in *GBA* carriers > controls. Red areas depicted on the brain surface template illustrate clusters of voxels of  $^{11}\text{C}$ -PK11195  $\text{BP}_{\text{ND}}$  surviving  $P < 0.05$  with FWE correction in cortical regions of *GBA*+ carriers compared with control subjects. *GBA*+,  $n = 9$ ; controls,  $n = 20$ . (D) Bottom right, scatterplots of  $^{11}\text{C}$ -PK11195  $\text{BP}_{\text{ND}}$  in the substantia nigra of *GBA*+ carriers against University of Pennsylvania Smell Identification Test (UPSIT) score. *GBA*+ heterozygous carriers (white), biallelic *GBA*+ carriers (black). [Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

bilaterally in the occipital and temporal cortices, cerebellum, left hippocampus, and central and anterior mesencephalon (Table S3 and Fig. 1B,C). No brain regions showed reduced  $^{11}\text{C}$ -(R)-PK11195  $\text{BP}_{\text{ND}}$  compared with controls.

### No Difference in Mean $^{18}\text{F}$ -Dopa $\text{K}_i$ Between *GBA*+ and Control Participants

The *GBA* carriers showed no significant decreases in mean  $^{18}\text{F}$ -dopa  $\text{K}_i$  across striatal ROIs compared with controls (Tables S1 and S2, Fig. S1). Two participants had putamen and/or caudate  $^{18}\text{F}$ -dopa  $\text{K}_i$  more than 2 SDs below the control mean (Table S4). Greater variance in  $^{18}\text{F}$ -dopa  $\text{K}_i$  (see Table S1) was seen in the *GBA* group (SD of 0.002 in the putamen and caudate compared with SD of 0.001 in controls). Post hoc analysis (Student  $t$  test) comparing the anterior, medial, and posterior putamen did not show any significant mean differences between *GBA* mutation carriers and controls.

### No Correlation Between Nigral $^{11}\text{C}$ -(R)-PK11195 $\text{BP}_{\text{ND}}$ and $^{18}\text{F}$ -Dopa $\text{K}_i$ in *GBA*+ Group

There was no association between the SN  $^{11}\text{C}$ -(R)-PK11195  $\text{BP}_{\text{ND}}$  and putamen or caudate (Table S2)  $^{18}\text{F}$ -dopa  $\text{K}_i$  in the *GBA* group.

## Discussion

Our data indicate that both heterozygous and biallelic *GBA* mutation carriers can have increased  $^{11}\text{C}$ -(R)-PK11195  $\text{BP}_{\text{ND}}$  in brain regions susceptible to Lewy body formation.<sup>26</sup> It is unclear whether this is a cytotoxic or neuroprotective process. Only 10%–30% of *GBA* mutation carriers will develop PD. It is therefore unlikely that all the participants in this study will convert. Which *GBA* carriers are likely to progress to PD and the mechanisms underlying this conversion are of particular interest.

$^{11}\text{C}$ -(R)-PK11195  $\text{BP}_{\text{ND}}$  values in the SN correlated with UPSIT scores, suggesting that those *GBA* carriers who have reduced olfactory function have higher nigral inflammation. Correlation of striatal  $^{11}\text{C}$ -(R)-PK11195

BP<sub>ND</sub> with age and MDS UPDRS III score has also been shown in early PD cases.<sup>27</sup>

Despite mean nigral <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub> being increased in the *GBA* group, no significant reduction in mean putamen <sup>18</sup>F-dopa uptake was seen. It is known that <sup>18</sup>F-dopa lacks the sensitivity to detect early dopaminergic dysfunction because of compensatory upregulation of dopa decarboxylase in the remaining terminals. Early reductions may be better detected with dopamine transporter markers.<sup>28,29</sup> Our finding of normal striatal F-dopa uptake in *GBA* carriers may not necessarily equate to normal dopamine terminal function, although no *GBA* carrier exhibited clinical features of PD.

Interestingly <sup>18</sup>F-dopa Ki was more variable in the *GBA* group compared with controls. Recently, 184 non-manifesting *GBA* carriers were reported to have increased dopamine transporter binding across striatal regions.<sup>15</sup> This is in line with an increase in striatal <sup>18</sup>F-dopa Ki found in a portion of our *GBA*+ cases. It has been reported that <sup>11</sup>C-(R)-PK11195 binding to microglia “burns out” as amyloidosis in early Alzheimer’s disease advances<sup>30</sup> but increases again as tau tangles form.<sup>31,32</sup> A biphasic trajectory could explain the lack of correlation between <sup>18</sup>F-dopa Ki and <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub> in our data set.

### Limitations

The relatively small sample size, its cross-sectional design, and the unknown future disease status of *GBA* mutation carriers are limitations. We acknowledge that *GBA* mutations exhibit a variable penetrance and phenotype, in terms of both PD and GD. Reproducing these results in larger (ideally prospective) and more genotypically and phenotypically homogenous cohorts is needed. Nevertheless, we believe these are important and highly relevant pilot data that will inform the design of future studies.

The <sup>11</sup>C-PK11195 BP<sub>ND</sub> has high nonspecific binding, which provides a lower specific-to-background PET signal ratio than newer markers of activated microglia; therefore, our results may underestimate glial activation. This study used <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub> as a marker of the translocator protein (TSPO) expressed by the mitochondria of activated microglia, and, in contrast to newer TSPO tracers available, the binding is not influenced by the polymorphism of the TSPO expressed by individuals. The limitations of supervised cluster analysis in conditions with possible widespread microglial activation should also be acknowledged, as it could lead to an underestimation of <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub>, particularly in small ROIs.

Three of 5 and 2 of 5 subjects were taking substrate reduction therapy or enzyme replacement therapy (ERT), respectively. The former is under evaluation as a PD neuroprotective agent (clinicaltrials.gov, NCT02906020).

ERT is not thought to cross the blood–brain barrier, although 1 report suggests a portion may.<sup>33</sup> We cannot exclude the possibility that the reduced nigral and putamen <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub> in biallelic compared with heterozygous cases could represent suppression of glial activation by these drugs.

## Conclusions

Our findings indicate that *GBA* mutations are associated with microglial activation in Lewy-susceptible brain regions in subjects without either a prodromal or clinical diagnosis of PD. Further studies are required to assess whether <sup>11</sup>C-(R)-PK11195 BP<sub>ND</sub> PET, (with or without additional biomarkers) can predict *GBA* carrier conversion to PD and striatal dopamine loss. ■

**Acknowledgments:** We thank the staff members of the lysosomal storage unit of the Royal Free Hospital for their help and assistance in patient recruitment.

## Data and Materials Availability

Study data are available on reasonable request. ■

## References

1. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. *Brain* 2009; 132(Pt 7):1783–1794.
2. Lesage S, Anheim M, Condroyer C, et al. Large-scale screening of the Gaucher’s disease-related glucocerebrosidase gene in Europeans with Parkinson’s disease. *Hum Mol Genet* 2011;20(1): 202–210.
3. Mata IF, Samii A, Schneer SH, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. *Arch Neurol* 2008;65 (3):379–382.
4. Anheim M, Elbaz A, Lesage S, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. *Neurology* 2012;78(6): 417–420.
5. Rosenbloom B, Balwani M, Bronstein JM, et al. The incidence of parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher registry. *Blood Cells Mol Dis* 2011;46(1): 95–102.
6. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson’s syndrome in type I Gaucher disease. *QJM* 1996;89(9):691–694.
7. Cilia R, Tunesi S, Marotta G, et al. Survival and dementia in *GBA*-associated Parkinson’s disease: the mutation matters. *Ann Neurol* 2016;80(5):662–673.
8. Wong K, Sidransky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. *Mol Genet Metab* 2004;82(3):192–207.
9. Kraoua I, Stirnemann J, Ribeiro MJ, et al. Parkinsonism in Gaucher’s disease type 1: ten new cases and a review of the literature. *Mov Disord* 2009;24(10):1524–1530.
10. Goker-Alpan O, Masdeu JC, Kohn PD, et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. *Brain* 2012;135(Pt 8):2440–2448.
11. Kono S, Ouchi Y, Terada T, et al. Functional brain imaging in glucocerebrosidase mutation carriers with and without parkinsonism. *Mov Disord* 2010;25(12):1823–1829.

12. Sunwoo M-K, Kim S-M, Lee S, Lee PH. Parkinsonism associated with glucocerebrosidase mutation. *J Clin Neurol* 2011;7(2):99–101.
13. McNeill A, Wu R-M, Tzen K-Y, et al. Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. *PLoS One* 2013;8(7):e69190.
14. Simuni T, Brumm MC, Uribe L, et al. Clinical and dopamine transporter imaging characteristics of leucine-rich repeat kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's disease participants in the Parkinson's progression markers initiative: a cross-sectional study. *Mov Disord*. 2020;35(5):833–844.
15. Simuni T, Uribe L, Cho HR, et al. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's progression markers initiative (PPMI): a cross-sectional study. *Lancet Neurol* 2020;19(1):71–80.
16. McNeill A, Duran R, Proukakis C, et al. Hyposmia and cognitive impairment in Gaucher disease patients and carriers. *Mov Disord* 2012;27(4):526–532.
17. Mullin S, Beavan M, Bestwick J, et al. Evolution and clustering of prodromal parkinsonian features in GBA carriers. *Mov Disord*. 2019;34(9):1365–1373.
18. Avenali M, Toffoli M, Mullin S, et al. Evolution of prodromal parkinsonian features in a cohort GBA mutation-positive individuals: a 6-year longitudinal study. *J Neurol Neurosurg Psychiatr* 2019;90(10):1091.
19. Beavan M, McNeill A, Proukakis C, et al. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. *JAMA Neurol*. 2015;72(2):201–208.
20. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. *Mov Disord* 2015;30(12):1600–1611.
21. Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson's disease. *Parkinsonism Relat Disord* 2005;11(Suppl 1):S9–S15.
22. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? *Lancet Neurol* 2009;8(4):382–397.
23. Stokholm MG, Iranzo A, Østergaard K, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. *Lancet Neurol* 2017;16(10):789–796.
24. Mistry PK, Liu J, Yang M, et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. *Proc Natl Acad Sci U S A* 2010;107(45):19473–19478.
25. Parbo P, Ismail R, Hansen KV, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. *Brain* 2017;140(7):2002–2011.
26. Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. *Parkinsonism Relat Disord* 2007;13(Suppl 3):S221–S224.
27. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. *Ann Neurol* 2005;57(2):168–175.
28. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. *Brain* 2005;128(12):2777–2785.
29. Sossi V, de la Fuente-Fernández R, Nandhagopal R, et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. *Mov Disord* 2010;25(16):2717–2723.
30. team TCI, Lagarde J, Sarazin M, et al. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18 F-DPA-714 PET imaging. *Brain* 2016;139(4):1252–1264.
31. Fan Z, Brooks DJ, Okello A, Edison P. An early and late peak in microglial activation in Alzheimer's disease trajectory. *Brain* 2017;140(3):792–803.
32. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. *Neurobiol Dis* 2006;21(2):404–412.
33. Vogler C, Levy B, Grubb JH, et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. *Proc Natl Acad Sci U S A* 2005;102(41):14777.

## Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.